| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 12, 2021- Strengthened balance sheet with the completion of a successful IPO
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data...
-
Apr 21, 2021
Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the...
-
Apr 16, 2021
Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion...
-
Mar 1, 2021Former Goldman Sachs executive to serve as Chairman of Recursion's Board, effective immediately
Recursion, a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of Directors. Dr. Chavez, who joined Recursion's...
-
Feb 18, 2021Former VP & Assistant General Counsel at Pfizer to join Recursion's executive team
Recursion, a biotechnology company scaling more like a technology company, today announced the appointment of Louisa Daniels, J.D., MBA as its Chief Legal Officer and General Counsel. In her new...